Evidence map›Paper›PMID 30584267›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2018

The burden of neovascular age-related macular degeneration: a patient's perspective.

Kimberly L Spooner, Cleopatra T Mhlanga, Thomas H Hong, Geoffrey K Broadhead, Andrew A Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Efficacy and Safety of Biosimilar Ranibizumab (OPTIMABClinical ophthalmology (Auckland, N.Z.) · 2024
    Trial
  9. Trial
  10. Article
  11. Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  12. Article
  13. Article
  14. Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kimberly L SpoonerSydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia, achang@sydneyretina.com.au.
Cleopatra T MhlangaSydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia, achang@sydneyretina.com.au.
Thomas H HongSydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia, achang@sydneyretina.com.au.
Geoffrey K BroadheadSydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia, achang@sydneyretina.com.au.
Andrew A ChangSydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia, achang@sydneyretina.com.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.

methodsA total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.

resultsAll patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients' subjective decline in quality of vision.

conclusionManagement of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact.

Indexed as

age-related macular degenerationanti-VEGFAustraliaburdenpatient perspectivetreatment

Identifiers

PMID30584267
PMCPMC6287411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.